Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Return on Sales (2019 - 2025)

Bioadaptives' Return on Sales history spans 7 years, with the latest figure at 81.93% for Q3 2025.

  • For Q3 2025, Return on Sales fell 7016.0% year-over-year to 81.93%; the TTM value through Sep 2025 reached 152.37%, down 14060.0%, while the annual FY2024 figure was 54.78%, 4526.0% down from the prior year.
  • Return on Sales for Q3 2025 was 81.93% at Bioadaptives, down from 49.06% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.65% in Q4 2023 and bottomed at 1196.21% in Q1 2025.
  • The 5-year median for Return on Sales is 46.26% (2023), against an average of 107.0%.
  • The largest YoY upside for Return on Sales was 11531bps in 2025 against a maximum downside of -118750bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 23.27% in 2021, then decreased by -26bps to 29.33% in 2022, then soared by 109bps to 2.65% in 2023, then plummeted by -2045bps to 51.58% in 2024, then plummeted by -59bps to 81.93% in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Return on Sales are 81.93% (Q3 2025), 49.06% (Q2 2025), and 1196.21% (Q1 2025).